Exelixis Stock Current Asset
| EXEL Stock | USD 34.83 0.18 0.52% |
Exelixis fundamentals help investors to digest information that contributes to Exelixis' financial success or failures. It also enables traders to predict the movement of Exelixis Stock. The fundamental analysis module provides a way to measure Exelixis' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Exelixis stock.
Non Current Assets Total is expected to rise to about 1.7 B this year. Other Current Assets is expected to rise to about 71.3 M this year. Exelixis | Current Asset |
Exelixis Company Current Asset Analysis
Exelixis' Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Current Exelixis Current Asset | 178.66 M |
Most of Exelixis' fundamental indicators, such as Current Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Exelixis is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Exelixis Current Asset Historical Pattern
Today, most investors in Exelixis Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Exelixis' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current asset growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Exelixis current asset as a starting point in their analysis.
Exelixis Current Asset |
| Timeline |
Current Asset is important to company's creditors and private equity firms as they will often be interested in how much that company has in current assets since these assets can be easily liquidated in case the company goes bankrupt. However, it is usually not enough to know if a company is in good shape just based on current asset alone; the amount of current liabilities should always be considered.
| Competition |
Exelixis Total Assets
Total Assets |
|
In accordance with the recently published financial statements, Exelixis has a Current Asset of 178.66 M. This is 91.7% lower than that of the Biotechnology sector and 83.15% lower than that of the Health Care industry. The current asset for all United States stocks is 98.09% higher than that of the company.
Exelixis Current Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Exelixis' direct or indirect competition against its Current Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Exelixis could also be used in its relative valuation, which is a method of valuing Exelixis by comparing valuation metrics of similar companies.Exelixis is currently under evaluation in current asset category among its peers.
Exelixis ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Exelixis' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Exelixis' managers, analysts, and investors.Environmental | Governance | Social |
Exelixis Fundamentals
| Return On Equity | 0.2 | ||||
| Return On Asset | 0.13 | ||||
| Profit Margin | 0.22 % | ||||
| Operating Margin | 0.35 % | ||||
| Current Valuation | 8.83 B | ||||
| Shares Outstanding | 285.58 M | ||||
| Shares Owned By Insiders | 1.60 % | ||||
| Shares Owned By Institutions | 89.06 % | ||||
| Number Of Shares Shorted | 9.12 M | ||||
| Price To Earning | 48.17 X | ||||
| Price To Book | 4.32 X | ||||
| Price To Sales | 4.75 X | ||||
| Revenue | 1.83 B | ||||
| Gross Profit | 1.55 B | ||||
| EBITDA | 196.6 M | ||||
| Net Income | 207.76 M | ||||
| Cash And Equivalents | 1.53 B | ||||
| Cash Per Share | 4.77 X | ||||
| Total Debt | 189.94 M | ||||
| Debt To Equity | 0.07 % | ||||
| Current Ratio | 6.08 X | ||||
| Book Value Per Share | 7.96 X | ||||
| Cash Flow From Operations | 333.32 M | ||||
| Short Ratio | 4.03 X | ||||
| Earnings Per Share | 1.55 X | ||||
| Price To Earnings To Growth | 2.50 X | ||||
| Target Price | 31.83 | ||||
| Number Of Employees | 1.31 K | ||||
| Beta | 0.51 | ||||
| Market Capitalization | 9.9 B | ||||
| Total Asset | 2.94 B | ||||
| Retained Earnings | (173.35 M) | ||||
| Working Capital | 923.68 M | ||||
| Current Asset | 178.66 M | ||||
| Current Liabilities | 52.25 M | ||||
| Net Asset | 2.94 B |
About Exelixis Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Exelixis's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Exelixis using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Exelixis based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Exelixis Piotroski F Score and Exelixis Altman Z Score analysis. For more information on how to buy Exelixis Stock please use our How to buy in Exelixis Stock guide.You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Exelixis. If investors know Exelixis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Exelixis listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 121.699 | Earnings Share 1.55 | Revenue Per Share 7.032 | Quarterly Revenue Growth 0.143 | Return On Assets 0.1281 |
The market value of Exelixis is measured differently than its book value, which is the value of Exelixis that is recorded on the company's balance sheet. Investors also form their own opinion of Exelixis' value that differs from its market value or its book value, called intrinsic value, which is Exelixis' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Exelixis' market value can be influenced by many factors that don't directly affect Exelixis' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Exelixis' value and its price as these two are different measures arrived at by different means. Investors typically determine if Exelixis is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Exelixis' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.